This addendum provides additional data not available when this evidence report was finalized. A “bridge search” by the systematic evidence review teams identified newly published data from the Japanese Primary Prevention Project (JPPP) trial (Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S et al. Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial. JAMA. 2014;312:2510-20). These data are incorporated into the journal manuscripts based on the systematic evidence reviews (Chubak J, Whitlock EP, Williams SB, et al. Aspirin for the prevention of cancer incidence and mortality: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015. [In press]; Guirguis-Blake JM, Evans CV, Senger CA, et al. Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2015. [In press]; Whitlock EP, Burda BU, Williams SB. Bleeding risks with aspirin use for primary prevention in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann of Intern Med 2015. [In press]), and a supplemental analysis using these new data is included in the manuscript derived from this report (Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin for the primary prevention of cardiovascular disease and colorectal cancer: a decision analysis for the U.S. Preventive Services Task Force. Ann Intern Med. 2015. [In press]). Addendum Table 1 compares the key benefit and harm parameters between the base-case analysis and the supplemental analysis that includes evidence from the JPPP trial. Addendum Tables 2-12 contain comprehensive results from the supplemental analysis. Addendum Tables 2-4 correspond with Tables 4-6 of the base-case analysis described in this report, and Addendum Tables 5-12 correspond with Appendix A Tables 5-12.

Addendum Table 1

Comparison of Benefit and Harm Parameters Between Base and Supplemental Cases.

Addendum Table 2

Lifetime Net Benefit of Aspirin for Men and Women, Supplemental Case.

Addendum Table 3

Net Benefit of Aspirin Over 20 Years for Men and Women, Supplemental Case.

Addendum Table 4

Net Benefit of Aspirin Over 10 Years for Men and Women, Supplemental Case.

Addendum Table 5

Detailed Benefits and Harms From Aspirin Use for Men Aged 40-49 Years, Supplemental Case.

Addendum Table 6

Detailed Benefits and Harms From Aspirin Use for Women Aged 40-49 Years, Supplemental Case.

Addendum Table 7

Detailed Benefits and Harms From Aspirin Use for Men Aged 50-59 Years, Supplemental Case.

Addendum Table 8

Detailed Benefits and Harms From Aspirin Use for Women Aged 50-59 Years, Supplemental Case.

Addendum Table 9

Detailed Benefits and Harms From Aspirin Use for Men Aged 60-69 Years, Supplemental Case.

Addendum Table 10

Detailed Benefits and Harms From Aspirin Use for Women Aged 60-69 Years, Supplemental Case.

Addendum Table 11

Detailed Benefits and Harms From Aspirin Use for Men Aged 70-79 Years, Supplemental Case.

Addendum Table 12

Detailed Benefits and Harms From Aspirin Use for Women Aged 70-79 Years, Supplemental Case.